ROIV

SEC source: 0001635088-26-000071 · wk-form4_1782512028.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,659,297

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.23 to $33.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001635088-26-000071 · wk-form4_1782512028.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,813,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001635088-26-000067 · wk-form4_1782263780.xml · nonDerivative · entry 1

Humes Jennifer · CIK 0002058012 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,782

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000069 · wk-form4_1782263852.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 276,420

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · derivative · entry 4

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,444,834

Underlying: Common Stock · 200,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested.

SEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · nonDerivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,613,063

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,813,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001635088-26-000064 · wk-form4_1779488534.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278,549

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,613,063

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000042 · wk-form4_1776896770.xml · derivative · entry 2

Humes Jennifer · CIK 0002058012 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,157

Underlying: Common Shares · 27,157 shares

Expires 2036-04-19

F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2026. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in thirty-six (36) successive equal monthly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through each applicable vesting date.

SEC source: 0001635088-26-000042 · wk-form4_1776896770.xml · nonDerivative · entry 1

Humes Jennifer · CIK 0002058012 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,364

F1 · shares: Reflects an award of restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2026. These RSUs vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in twelve (12) successive equal quarterly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through each applicable vesting date.

SEC source: 0001635088-26-000043 · wk-form4_1776896805.xml · derivative · entry 2

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,026

Underlying: Common Shares · 84,026 shares

Expires 2036-04-19

F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2026. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in thirty-six (36) successive equal monthly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001635088-26-000043 · wk-form4_1776896805.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,511

F1 · shares: Reflects an award of restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2026. These RSUs vest (i) 25% on the first anniversary of the vesting commencement date and (ii) in twelve (12) successive equal quarterly installments thereafter, measured from the first anniversary of the vesting commencement date, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001635088-26-000044 · wk-form4_1776896865.xml · derivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,644,834

Underlying: Common Stock · 200,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested.

SEC source: 0001635088-26-000044 · wk-form4_1776896865.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,647,546

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001635088-26-000044 · wk-form4_1776896865.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,847,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001807359-26-000006 · wk-form4_1776810842.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,474

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

SEC source: 0001209181-26-000003 · wk-form4_1776810776.xml · nonDerivative · entry 2

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,405

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001209181-26-000003 · wk-form4_1776810776.xml · nonDerivative · entry 1

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,499

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

SEC source: 0001140361-26-015985 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,229

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-26-015985 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,324

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

SEC source: 0001635088-26-000038 · wk-form4_1776724041.xml · nonDerivative · entry 1

Gline Matthew · CIK 0001750094 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,736,116

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.98 to $29.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001140361-26-014301 · form4.xml · nonDerivative · entry 1

Humes Jennifer · CIK 0002058012 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,191

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $28.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,677,617

F4 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · nonDerivative · entry 3

Gline Matthew · CIK 0001750094 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,025,890

F4 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000036 · wk-form4_1775171687.xml · nonDerivative · entry 1

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,576,512

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · derivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 58,391 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.exercise_price: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · shares: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.exercise_date: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F5 · derivative.exercise_date: Award of CVARs is fully vested.

F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.underlying_shares: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,865,129

F3 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs.

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,894,938

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · kind: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · price: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

SEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · derivative · entry 4

Gline Matthew · CIK 0001750094 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 97,319 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.exercise_price: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · shares: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.exercise_date: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F5 · derivative.exercise_date: Award of CVARs is fully vested.

F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.underlying_shares: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

SEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · nonDerivative · entry 2

Gline Matthew · CIK 0001750094 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,330,574

F3 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs.

SEC source: 0001635088-26-000034 · wk-form4_1775085629.xml · nonDerivative · entry 1

Gline Matthew · CIK 0001750094 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,384,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · kind: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · price: On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

SEC source: 0001140361-26-012063 · form4.xml · derivative · entry 3

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,578

Underlying: Common Stock · 70,000 shares

Expires 2033-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

SEC source: 0001140361-26-012063 · form4.xml · nonDerivative · entry 2

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,963

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.32 to $27.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001140361-26-012063 · form4.xml · nonDerivative · entry 1

Fitzgerald Meghan · CIK 0001349297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001635088-26-000029 · wk-form4_1774393670.xml · nonDerivative · entry 1

Humes Jennifer · CIK 0002058012 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,729

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000030 · wk-form4_1774393730.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,867

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000026 · wk-form4_1773959801.xml · derivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,844,834

Underlying: Common Stock · 200,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001635088-26-000026 · wk-form4_1773959801.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,647,546

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.04 to $28.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001635088-26-000026 · wk-form4_1773959801.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,847,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001807359-26-000004 · wk-form4_1773872606.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,804

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

SEC source: 0001635088-26-000019 · wk-form4_1771897216.xml · derivative · entry 9

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,026,184

Underlying: Common Shares · 587,390 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).

SEC source: 0001635088-26-000019 · wk-form4_1771897216.xml · nonDerivative · entry 6

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,736,547

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

F4 · price: These Common Shares were sold in multiple transactions at prices ranging from $27.14 to $27.80, inclusive.

SEC source: 0001635088-26-000019 · wk-form4_1771897216.xml · nonDerivative · entry 5

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,323,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001635088-26-000019 · wk-form4_1771897216.xml · derivative · entry 8

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,613,574

Underlying: Common Shares · 1,012,610 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).

SEC source: 0001635088-26-000019 · wk-form4_1771897216.xml · nonDerivative · entry 4

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,736,547

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

F3 · price: These Common Shares were sold in multiple transactions at prices ranging from $26.70 to $27.45, inclusive.

SEC source: 0001635088-26-000019 · wk-form4_1771897216.xml · nonDerivative · entry 3

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,749,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001635088-26-000023 · wk-form4_1771976631.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,413

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000022 · wk-form4_1771976596.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,647,546

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001635088-26-000019 · wk-form4_1771897216.xml · derivative · entry 7

Torti Frank · CIK 0001647805 · President and Vant Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,626,184

Underlying: Common Shares · 1,400,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).